Completed PHASE4 INTERVENTIONAL 1-arm NCT00599079

Azithromycin in the Treatment of M. Avium Complex Lung Disease

Open, Noncomparative Trial of Azithromycin in the Treatment of M.Avium Complex (MAC) Lung Disease

Sponsor: Pfizer

Conditions Mycobacterium Avium Complex Lung Disease

Updated 7 times since 2017 Last updated: May 19, 2017 Started: Feb 28, 1993 Primary completion: May 31, 2008 Completion: May 18, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Mycobacterium Avium Complex Lung Disease and is currently completed. Pfizer leads this study, which shows 7 recorded versions since 1993 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jul 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Feb 2017 — Jul 2017 [monthly]

Unknown Status PHASE4
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

Feb 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
The University of Texas Health Science Center at Tyler

Data source: The University of Texas Health Science Center at Tyler

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tyler, United States